-
公开(公告)号：US10980853B2
公开(公告)日：2021-04-20
申请号：US16067376
申请日：2015-12-31
发明人： Dai-Hua Tsai , Tzung Hsien Lai , Tsui Hsu Chan , Yuh Shan Chung , Li-Chuan Hsu
IPC分类号： A61K36/28 , A61K36/00 , A61K31/513 , A61K45/06 , A61K31/704 , A61P35/00 , A61K9/14
摘要： The present invention provides a process for the preparation of a Crassocephalum crepidioides extract, and the extract prepared thereby. The present invention further relates to a pharmaceutical composition/combination comprising the Crassocephalum crepidioides extract. The use of the extract and the composition/combination comprising the extract in the prevention or treatment of cancer is also provided.
-
公开(公告)号：US10745360B2
公开(公告)日：2020-08-18
申请号：US15326490
申请日：2015-06-15
发明人： Nan-Horng Lin , Chu-Bin Liao , Shao-Zheng Peng , Shih-Chieh Yen , Mann-Yan Kuo
IPC分类号： C07D241/44 , C07D401/12 , A61P35/00 , C07D413/04 , C07D413/12 , A61P9/00 , A61P19/02 , A61P3/10 , A61P13/12
摘要： A compound for treating a protein kinase-related disease or disorder having a structure of formula (I) wherein L is NR8 or O; R1, R2, R3, R4, R5, R6 and R7 are defined herein. Compounds of formula (I) are useful for inhibition of protein kinases. Methods of using compounds of formula (I), stereoisomers, tautomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
-
公开(公告)号：US20200164114A1
公开(公告)日：2020-05-28
申请号：US16636908
申请日：2017-08-09
发明人： Tur-Fu HUANG , Yu-Ju KUO , Woei-Jer CHUANG
摘要： Disclosed herein are disintegrin variants, and methods for suppressing or inhibiting platelet aggregation in a subject in need thereof. The method includes administering to the subject in need thereof an effective amount of the present disintegrin variant to alleviate or ameliorate symptoms associated with diseases, disorders, and/or conditions resulted from platelet aggregation. According to preferred embodiments, the present disintegrin variant is applied as a coating on an implantable device, such as a stent or a catheter.
-
公开(公告)号：US10174322B2
公开(公告)日：2019-01-08
申请号：US15549174
申请日：2016-02-23
发明人： Liang-Yi Hung , Chien-Hsien Lai , Ta-Chien Tseng , Jeng-Chang Lee , Bo-Wen Lin
摘要： Disclosed herein is novel double-stranded short interfering ribonucleic acid (siRNA) capable of suppressing the translation of Aurora-A mRNA. Also disclosed are use of the novel siRNA as disclosed herein for manufacturing a medicament suitable for treating a cancer, which is mediated through epidermal growth factor receptor (EGFR) signaling. Accordingly, a pharmaceutical composition comprising the disclosed novel siRNA molecules is provided; as well as a method of treating a subject suffering from EGFR-mediated cancer via administering to the subject the disclosed novel siRNA molecule.
-
公开(公告)号：US20140178360A1
公开(公告)日：2014-06-26
申请号：US14192301
申请日：2014-02-27
发明人： Mann-Yan KUO , Ying-Shuan Lee , Paonien Chen , Li Jung Chen , Yann Yu Lu , Yi-Ting Huang , Hung-Yi Hsu , Ping-Kuei Tsai
IPC分类号： C07D413/04 , A61K31/541 , A61K45/06 , A61K31/5377 , C07D413/14 , C07D417/14
CPC分类号： A61K31/5377 , A61K31/541 , A61K45/06 , C07D239/47 , C07D401/04 , C07D401/14 , C07D403/12 , C07D409/12 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/14 , A61K2300/00
摘要： The present invention relates to pyrimidine compounds of formula (I): which are useful in treating mTOR kinase- or PI3K kinase-related diseases.
摘要翻译： 本发明涉及式（I）的嘧啶化合物：其可用于治疗mTOR激酶或PI3K激酶相关疾病。
-
6.发明申请公开(公告)号：US20200087383A1
公开(公告)日：2020-03-19
申请号：US16616416
申请日：2018-05-22
发明人： Trai-Ming YEH , Yung-Chun CHUANG , Yen-Chung LAI
摘要： Disclosed herein is an anti-DENV antibody, a pharmaceutical composition comprising the same, and uses thereof. According to embodiments of the present disclosure, the anti-DENV antibody comprises a heavy chain variable region and a light chain variable region, in which the heavy chain variable region comprises amino acid sequences of SEQ ID NOs: 1-3, and the light chain variable region comprises amino acid sequences of SEQ ID NOs: 5-7.
-
公开(公告)号：US20190284141A1
公开(公告)日：2019-09-19
申请号：US16302021
申请日：2017-05-16
申请人： DCB-USA LLC
发明人： Che-Ming TENG , Jing-Ping LIOU , Shiow-Lin PAN , Chia-Ron YANG
IPC分类号： C07D215/38 , C07D215/12 , C07D215/26 , C07D217/02 , C07D217/22 , A61P35/00 , A61P31/00 , A61K9/00
摘要： Disclosed is hydroxamic acid compounds of Formula (I) set forth herein. Also disclosed are a pharmaceutical composition containing such a compound and a method of using the compound for treating a condition associated with histone deacetylase 6.
-
8.发明申请公开(公告)号：US20190060382A1
公开(公告)日：2019-02-28
申请号：US16067376
申请日：2015-12-31
发明人： Dai-Hua TSAI , Tzung Hsien LAI , Tsui Hsu CHAN , Yuh Shan CHUNG , Li-Chuan HSU
IPC分类号： A61K36/28 , A61K45/06 , A61K31/513 , A61K31/704 , A61P35/00 , A61K9/14
摘要： The present invention provides a process for the preparation of a Crassocephalum crepidioides extract, and the extract prepared thereby. The present invention further relates to a pharmaceutical composition/combination comprising the Crassocephalum crepidioides extract. The use of the extract and the composition/combination comprising the extract in the prevention or treatment of cancer is also provided.
-
![PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF BETA-GLUCURONIDASE](/abs-image/US/2018/08/02/US20180214426A1/abs.jpg.150x150.jpg)
公开(公告)号：US20180214426A1
公开(公告)日：2018-08-02
申请号：US15577201
申请日：2016-05-26
发明人： Yeh-Long Chen , Tian-Lu Cheng , Cherng-Chyi Tzeng , Chih-Hua Tseng , Ta-Chun Cheng , Kai-Wen Cheng , Wei-Fen Luo
IPC分类号： A61K31/437 , C07D471/04 , A61K45/06 , A61K31/055 , A61P35/00
CPC分类号： A61K31/437 , A61K31/03 , A61K31/055 , A61K45/06 , A61P35/00 , C07D471/04
摘要： The present invention provides novel pyrazolo[4,3-c]quinoline derivatives exhibiting specifically inhibition activity to microbiota β-glucuronidase, whereby providing potent activities to prevent chemotherapy-induced diarrhea (CID) of cancers. Therefore, the compounds of the present invention can be used as (1) chemotherapy-adjuvant to prevent chemotherapy-induced diarrhea (CID) and enhance chemotherapeutic efficiency of cancers; (2) health-food supplement to prevent the carcinogens induced colon carcinoma.
-
公开(公告)号：US20180037888A1
公开(公告)日：2018-02-08
申请号：US15549174
申请日：2016-02-23
发明人： Liang-Yi HUNG , Chien-Hsien LAI , Ta-Chien TSENG , Jeng-Chang LEE , Bo-Wen LIN
IPC分类号： C12N15/113 , C07H21/04 , A61K9/127
CPC分类号： C12N15/113 , A61K9/127 , A61K48/00 , C07H21/04 , C12N2310/14 , C12N2310/3231
摘要： Disclosed herein is novel double-stranded short interfering ribonucleic acid (siRNA) capable of suppressing the translation of Aurora-A mRNA. Also disclosed are use of the novel siRNA as disclosed herein for manufacturing a medicament suitable for treating a cancer, which is mediated through epidermal growth factor receptor (EGFR) signaling. Accordingly, a pharmaceutical composition comprising the disclosed novel siRNA molecules is provided; as well as a method of treating a subject suffering from EGFR-mediated cancer via administering to the subject the disclosed novel siRNA molecule.
-
-
-
-
-
-
-
-
-
搜索结果
38 条记录 (耗时 0.034 秒)
